PNP
Basic information
Region (hg38): 14:20461992-20477094
Previous symbols: [ "NP" ]
Links
Phenotypes
GenCC
Source:
- purine nucleoside phosphorylase deficiency (Supportive), mode of inheritance: AR
- purine nucleoside phosphorylase deficiency (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Purine nucleoside phosphorylase deficiency | AR | Allergy/Immunology/Infectious ; Oncologic | Antiinfectious prophylaxis and early and aggressive treatment of infections may be beneficial; Surveillance for malignancy (eg, lymphoma has been described) can be beneficial; BMT/HSCT has been reported | Allergy/Immunology/Infectious; Biochemical; Neurologic; Oncologic | 5579411; 825775; 102751; 111549; 6774252; 3029074; 1931007; 1384322; 8774508; 8931706; 9067751; 9737781; 11498751; 11453975; 11902746; 17910661; 18208442; 19584574; 19733163; 19657670; 20544539; 22132981 |
ClinVar
This is a list of variants' phenotypes submitted to
- Purine-nucleoside phosphorylase deficiency (12 variants)
- not provided (3 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PNP gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 41 | 44 | ||||
missense | 83 | 95 | ||||
nonsense | 8 | |||||
start loss | 0 | |||||
frameshift | 6 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 7 | 13 | 1 | 21 | ||
non coding | 11 | 24 | 13 | 49 | ||
Total | 12 | 14 | 96 | 68 | 16 |
Highest pathogenic variant AF is 0.0000394
Variants in PNP
This is a list of pathogenic ClinVar variants found in the PNP region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
14-20469375-G-A | Purine-nucleoside phosphorylase deficiency | Uncertain significance (Jan 12, 2018) | ||
14-20469396-C-A | Purine-nucleoside phosphorylase deficiency | Uncertain significance (Jan 13, 2018) | ||
14-20469429-G-A | Purine-nucleoside phosphorylase deficiency | Benign (Jan 12, 2018) | ||
14-20469434-G-T | Purine-nucleoside phosphorylase deficiency | Benign (Jan 12, 2018) | ||
14-20469442-C-G | Purine-nucleoside phosphorylase deficiency | Benign (Jan 12, 2018) | ||
14-20469528-G-C | Purine-nucleoside phosphorylase deficiency | Uncertain significance (Sep 01, 2021) | ||
14-20469534-G-C | Purine-nucleoside phosphorylase deficiency | Uncertain significance (Sep 27, 2023) | ||
14-20469537-T-A | Purine-nucleoside phosphorylase deficiency | Likely pathogenic (May 05, 2023) | ||
14-20469538-G-A | Purine-nucleoside phosphorylase deficiency | Uncertain significance (Jun 27, 2022) | ||
14-20469540-G-T | Purine-nucleoside phosphorylase deficiency | Uncertain significance (Jul 14, 2022) | ||
14-20469546-C-T | Purine-nucleoside phosphorylase deficiency | Likely benign (May 27, 2022) | ||
14-20469548-C-A | Purine-nucleoside phosphorylase deficiency | Likely benign (Feb 10, 2023) | ||
14-20469550-A-G | Purine-nucleoside phosphorylase deficiency | Likely benign (Jun 16, 2023) | ||
14-20469550-AGGCCCGCAG-A | Purine-nucleoside phosphorylase deficiency | Likely benign (Nov 08, 2023) | ||
14-20469553-C-T | Purine-nucleoside phosphorylase deficiency | Likely benign (Oct 25, 2023) | ||
14-20472290-A-T | not specified • Purine-nucleoside phosphorylase deficiency | Benign (Jan 29, 2024) | ||
14-20472292-AT-A | Purine-nucleoside phosphorylase deficiency | Benign (Nov 13, 2021) | ||
14-20472299-C-A | Benign (Nov 02, 2018) | |||
14-20472300-T-A | Purine-nucleoside phosphorylase deficiency | Likely benign (Apr 10, 2022) | ||
14-20472300-TC-T | Purine-nucleoside phosphorylase deficiency | Benign (Jul 17, 2023) | ||
14-20472301-C-A | Purine-nucleoside phosphorylase deficiency | Uncertain significance (Jan 12, 2018) | ||
14-20472302-C-T | Purine-nucleoside phosphorylase deficiency | Likely benign (Aug 23, 2022) | ||
14-20472307-G-C | Purine-nucleoside phosphorylase deficiency • Immunodeficiency due to purine nucleoside phosphorylase deficiency | Pathogenic/Likely pathogenic (Mar 14, 2024) | ||
14-20472309-T-C | Purine-nucleoside phosphorylase deficiency | Uncertain significance (Jul 05, 2022) | ||
14-20472311-C-T | Purine-nucleoside phosphorylase deficiency | Likely benign (Oct 27, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PNP | protein_coding | protein_coding | ENST00000361505 | 6 | 8141 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00000700 | 0.737 | 125719 | 0 | 29 | 125748 | 0.000115 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.439 | 146 | 162 | 0.903 | 0.00000861 | 1898 |
Missense in Polyphen | 51 | 60.787 | 0.83899 | 763 | ||
Synonymous | -0.0240 | 57 | 56.8 | 1.00 | 0.00000286 | 571 |
Loss of Function | 1.14 | 10 | 14.7 | 0.679 | 9.54e-7 | 135 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000116 | 0.000116 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.000149 | 0.000149 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.0000980 | 0.0000980 |
Other | 0.000326 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta- (deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate. {ECO:0000269|PubMed:2104852}.;
- Pathway
- Pyrimidine metabolism - Homo sapiens (human);Nicotinate and nicotinamide metabolism - Homo sapiens (human);Purine metabolism - Homo sapiens (human);Purine Nucleoside Phosphorylase Deficiency;Mercaptopurine Action Pathway;Azathioprine Action Pathway;Nicotinate and Nicotinamide Metabolism;Xanthine Dehydrogenase Deficiency (Xanthinuria);Adenylosuccinate Lyase Deficiency;AICA-Ribosiduria;Thioguanine Action Pathway;Adenine phosphoribosyltransferase deficiency (APRT);Mitochondrial DNA depletion syndrome;Myoadenylate deaminase deficiency;Purine Metabolism;Molybdenum Cofactor Deficiency;Adenosine Deaminase Deficiency;Gout or Kelley-Seegmiller Syndrome;Lesch-Nyhan Syndrome (LNS);Xanthinuria type I;Xanthinuria type II;miR-targeted genes in epithelium - TarBase;miR-targeted genes in leukocytes - TarBase;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in squamous cell - TarBase;Neutrophil degranulation;purine ribonucleosides degradation to ribose-1-phosphate;Nucleobase catabolism;Metabolism of nucleotides;purine deoxyribonucleosides degradation;guanosine nucleotides degradation;urate biosynthesis/inosine 5,-phosphate degradation;adenosine nucleotides degradation;purine nucleotides degradation;Innate Immune System;Immune System;Metabolism;Nicotinate Nicotinamide metabolism;guanine and guanosine salvage;Nucleotide salvage;Purine salvage;arsenate detoxification I (glutaredoxin);Purine nucleotides nucleosides metabolism;superpathway of purine nucleotide salvage;Purine catabolism;adenine and adenosine salvage III
(Consensus)
Recessive Scores
- pRec
- 0.352
Intolerance Scores
- loftool
- 0.289
- rvis_EVS
- 0.59
- rvis_percentile_EVS
- 82.51
Haploinsufficiency Scores
- pHI
- 0.423
- hipred
- N
- hipred_score
- 0.331
- ghis
- 0.398
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.965
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Pnp2
- Phenotype
Gene ontology
- Biological process
- nucleobase-containing compound metabolic process;inosine catabolic process;purine nucleotide catabolic process;nicotinamide riboside catabolic process;immune response;NAD biosynthesis via nicotinamide riboside salvage pathway;urate biosynthetic process;positive regulation of T cell proliferation;response to drug;purine-containing compound salvage;neutrophil degranulation;positive regulation of alpha-beta T cell differentiation;interleukin-2 secretion
- Cellular component
- extracellular region;nucleus;cytoplasm;cytosol;cytoskeleton;secretory granule lumen;extracellular exosome;ficolin-1-rich granule lumen
- Molecular function
- nucleoside binding;purine nucleobase binding;purine-nucleoside phosphorylase activity;drug binding;phosphate ion binding